📇 Rhumatologue · LA TRONCHE · (38) · Hospitalier

M JEAN-LUC BOSSON

Pourquoi vous devez consulter ce praticien

4 raisons identifiées

Auteur de référence en rhumatologie
38 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (6 thèses dirigées)
Expérience confirmée
31 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
120.1 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 LA TRONCHE (38)HospitalierRPPS 10003132932

EnseignementExpérience confirmée

31ans d'exercice (thèse 1995)

🇫🇷 Publications académiques françaises (8)🎓 6 thèses dirigées

✨ Génération du profil synthétique IA en cours…

Thèses universitaires

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Efficacy and Safety of Early Administration of 4-Factor Prothrombin Complex Concentrate in Patients With Trauma at Risk of Massive Transfusion: The PROCOAG Randomized Clinical Trial

JAMA · 2023

📚 83 citations🎯 RCR 14.86Top 1% NIH🩺 Clinique🔓 Open Access

Lire l'abstract Crossref ↓

ImportanceOptimal transfusion strategies in traumatic hemorrhage are unknown. Reports suggest a beneficial effect of 4-factor prothrombin complex concentrate (4F-PCC) on blood product consumption.ObjectiveTo investigate the efficacy and safety of 4F-PCC administration in patients at risk of massive transfusion.Design, Setting, and ParticipantsDouble-blind, randomized, placebo-controlled superiority trial in 12 French designated level I trauma centers from December 29, 2017, to August 31, 2021, involving consecutive patients with trauma at risk of massive transfusion. Follow-up was completed on August 31, 2021.InterventionsIntravenous administration of 1 mL/kg of 4F-PCC (25 IU of factor IX/kg) vs 1 mL/kg of saline solution (placebo). Patients, investigators, and data analysts were blinded to treatment assignment. All patients received early ratio-based transfusion (packed red blood cells:fresh frozen plasma ratio of 1:1 to 2:1) and were treated according to European traumatic hemorrhage guidelines.Main Outcomes and MeasuresThe primary outcome was 24-hour all blood product consumption (efficacy); arterial or venous thromboembolic events were a secondary outcome (safety).ResultsOf 4313 patients with the highest trauma level activation, 350 were eligible for emergency inclusion, 327 were randomized, and 324 were analyzed (164 in the 4F-PCC group and 160 in the placebo group). The median (IQR) age of participants was 39 (27-56) years, Injury Severity Score was 36 (26-50 [major trauma]), and admission blood lactate level was 4.6 (2.8-7.4) mmol/L; prehospital arterial systolic blood pressure was less than 90 mm Hg in 179 of 324 patients (59%), 233 patients (73%) were men, and 226 (69%) required expedient hemorrhage control. There was no statistically or clinically significant between-group difference in median (IQR) total 24-hour blood product consumption (12 [5-19] U in the 4F-PCC group vs 11 [6-19] U in the placebo group; absolute difference, 0.2 U [95% CI, −2.99 to 3.33]; P = .72). In the 4F-PCC group, 56 patients (35%) presented with at least 1 thromboembolic event vs 37 patients (24%) in the placebo group (absolute difference, 11% [95% CI, 1%-21%]; relative risk, 1.48 [95% CI, 1.04-2.10]; P = .03).Conclusions and RelevanceAmong patients with trauma at risk of massive transfusion, there was no significant reduction of 24-hour blood product consumption after administration of 4F-PCC, but thromboembolic events were more common. These findings do not support systematic use of 4F-PCC in patients at risk of massive transfusion.Trial RegistrationClinicalTrials.gov Identifier: NCT03218722

Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial

The Lancet. Neurology · 2023

📚 65 citations🎯 RCR 10.76Top 2% NIH🩺 Clinique

Development of artificial intelligence powered apps and tools for clinical pharmacy services: A systematic review

International journal of medical informatics · 2023

📚 46 citations🎯 RCR 8.91Top 3% NIH🔓 Open Access📄 PDF gratuit ↗

Cookies & analyse de trafic

M JEAN-LUC BOSSON

Pourquoi vous devez consulter ce praticien

Thèses universitaires

Direction de thèses

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (38) — classées par pathologie

Essai clinique14

Transversal14

Pharmacovigilance3

IA en rhumatologie2

Qualité de vie / PROMs2

Revue / méta-analyse2

Revue générale2

Activité physique / Rééducation1

Économie santé1

Épidémiologie & registres1

Gériatrie1

Pédiatrie1

Santé mentale / fatigue1

Vraie vie / RWE1

Datasets & protocoles partagés

Partager cette fiche